NIAID Awards $79.8M for Influenza Research and Surveillance Centers of Excellence

Contract Overview

Contract Amount: $79,763,886 ($79.8M)

Contractor: Icahn School of Medicine AT Mount Sinai

Awarding Agency: Department of Health and Human Services

Start Date: 2014-01-09

End Date: 2022-08-01

Contract Duration: 3,126 days

Daily Burn Rate: $25.5K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 10

Pricing Type: COST NO FEE

Sector: R&D

Official Description: IGF::OT::IGF NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)

Place of Performance

Location: NEW YORK, NEW YORK County, NEW YORK, 10029

State: New York Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $79.8 million to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI for work described as: IGF::OT::IGF NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS) Key points: 1. Significant investment in critical public health research. 2. Competition method indicates broad market interest. 3. Long-term contract duration suggests ongoing need. 4. Focus on biotechnology R&D aligns with sector trends.

Value Assessment

Rating: good

The total award of $79.8M over approximately 8.6 years for research and development is substantial. Benchmarking against similar large-scale R&D contracts is difficult without more specific cost breakdowns, but the 'Cost No Fee' contract type suggests the government is primarily focused on achieving research objectives rather than strict cost control.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting multiple qualified bidders participated. This method generally leads to better price discovery and ensures the government receives competitive proposals.

Taxpayer Impact: The investment supports critical research that could lead to significant public health benefits, potentially saving taxpayer money in the long run through disease prevention and management.

Public Impact

Enhances national capacity to monitor and combat influenza. Supports advanced scientific research and innovation. Contributes to global health security by tracking viral threats. Fosters collaboration between research institutions and government agencies.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This contract falls within the Research and Development in Biotechnology sector, a high-growth area focused on biological sciences and technologies. Spending in this sector is often characterized by long-term investments and significant innovation potential, with benchmarks varying widely based on project scope and novelty.

Small Business Impact

The data does not indicate specific subcontracting opportunities for small businesses. Given the nature of large-scale research centers of excellence, prime contract awards are typically made to established institutions, but opportunities may exist further down the subcontracting chain.

Oversight & Accountability

The National Institutes of Health (NIH) is responsible for overseeing this contract. Oversight would likely involve monitoring research progress, adherence to grant terms, and financial accountability to ensure taxpayer funds are used effectively for the stated research goals.

Related Government Programs

Risk Flags

Tags

research-and-development-in-biotechnolog, department-of-health-and-human-services, ny, definitive-contract, 10m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $79.8 million to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI. IGF::OT::IGF NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)

Who is the contractor on this award?

The obligated recipient is ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $79.8 million.

What is the period of performance?

Start: 2014-01-09. End: 2022-08-01.

What is the expected return on investment for this influenza research funding in terms of disease prevention or economic impact?

Quantifying the precise ROI for R&D is challenging due to the inherent uncertainty of scientific discovery. However, successful influenza research can lead to more effective vaccines and treatments, reducing healthcare costs, lost productivity, and mortality. The economic impact of preventing even a single major influenza pandemic would far outweigh the $79.8M investment.

What are the primary risks associated with the long duration and 'Cost No Fee' nature of this contract?

The primary risks include potential cost overruns if research proves more complex than anticipated, and the 'Cost No Fee' structure might disincentivize extreme cost-efficiency. Additionally, the long duration (over 8 years) increases the risk of research becoming outdated or shifting priorities, requiring adaptive management and clear milestone tracking.

How will the effectiveness of the Centers of Excellence be measured and ensured?

Effectiveness will likely be measured through scientific output (publications, patents), the development of new diagnostic tools or therapies, contributions to public health surveillance data, and the successful training of researchers. Regular scientific reviews, progress reports, and adherence to NIH research standards will be key to ensuring accountability and effectiveness.

Industry Classification

NAICS: Professional, Scientific, and Technical ServicesScientific Research and Development ServicesResearch and Development in Biotechnology

Product/Service Code: RESEARCH AND DEVELOPMENTN – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: BASIC RESEARCH

Offers Received: 10

Pricing Type: COST NO FEE (S)

Evaluated Preference: NONE

Contractor Details

Address: ONE GUSTAVE L LEVY PL, NEW YORK, NY, 10029

Business Categories: Category Business, Corporate Entity Tax Exempt, Educational Institution, Higher Education, Nonprofit Organization, Not Designated a Small Business, Higher Education (Private)

Financial Breakdown

Contract Ceiling: $182,025,770

Exercised Options: $79,763,886

Current Obligation: $79,763,886

Actual Outlays: $11,877,985

Subaward Activity

Number of Subawards: 18

Total Subaward Amount: $47,872,805

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: YES

Timeline

Start Date: 2014-01-09

Current End Date: 2022-08-01

Potential End Date: 2023-05-24 00:00:00

Last Modified: 2025-09-22

More Contracts from Icahn School of Medicine AT Mount Sinai

View all Icahn School of Medicine AT Mount Sinai federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending